Trial Profile

A dose-ascending study of KP879 for the treatment of Stimulant Use Disorder (SUD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Serdexmethylphenidate (Primary)
Indications Substance-related disorders
Focus Adverse reactions; Therapeutic Use
Sponsors KemPharm; Zevra Therapeutics

Most Recent Events

22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
21 Mar 2022 According to a KemPharm media release, The full data and detailed results are expected to be submitted for presentation at future scientific conferences and publication in peer-reviewed journals
21 Mar 2022 Results published in the KemPharm Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com